NB
Nessan Bermingham
Executive Vice President, Corporate Strategy & External Innovation
Intellia TherapeuticsRoles
Therapeutic Areas
Intellia Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NTLA-2001 | Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | Phase 3 |
| NTLA-2002 | Hereditary Angioedema (HAE) | Phase 2 |
| NTLA-3001 | Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease | Phase 1/2 |
| NTLA-5001 | Acute Myeloid Leukemia (AML) | Phase 1/2 |
| NTLA-6001 | CD30+ Lymphomas | Preclinical |
| NTLA-4001 | Glycogen Storage Disease Type Ia (GSDIa) | Research/Preclinical |
Leadership Team at Intellia Therapeutics
JL
John Leonard
President and Chief Executive Officer
LS
Laura Sepp-Lorenzino
Executive Vice President and Chief Scientific Officer
GG
Glenn Goddard
Executive Vice President and Chief Financial Officer
DL
David Lebwohl
Executive Vice President and Chief Medical Officer
AB
Andrew B. Finn
Executive Vice President, Product Development & Operations
JB
James B. Chung
Senior Vice President, Regulatory Affairs & Quality Assurance
DH
Derek Hicks
Senior Vice President, General Counsel and Secretary
DB
David B. Singer
Chairman of the Board of Directors
CS
Carrie S. Cox
Board Member
FV
Frank Verwiel
Board Member